-
Sector Analysis
NewHeart Failure Epidemiology Analysis and Forecast to 2032
Heart Failure Report Overview In the 7MM, there were 3,094,817 diagnosed incident cases of heart failure in 2022. The market is expected to grow at an AGR of more than 1% during 2022-2032. The Heart Failure market research report provides an overview of the risk factors, comorbidities, and global and historical epidemiological trends for heart failure in the seven major markets namely the US, France, Germany, Italy, Spain, UK, and Japan. The report also includes a 10-year epidemiology forecast for...
-
Sector Analysis
Atrial Fibrillation Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2032
Atrial Fibrillation Market Report Overview Atrial Fibrillation market size across the 8MM was valued at $14.53 billion in 2022 and is expected to decline at a CAGR of more than 1% during 2022-2032. Atrial fibrillation (AF) is clinically defined as an irregular and often rapid heart rhythm caused by the degeneration of electrical impulses in the atria. This disorganized electrical activity of the atria results in accelerated and irregular ventricular activity, loss of atrial mechanical function, and increased risk of...
-
Sector Analysis
Venous Thromboembolism (VTE) Epidemiology Analysis and Forecast to 2032
Venous Thromboembolism (VTE) Market Report Overview In the 7MM, there were 1,469,547 diagnosed incident cases of VTE in 2022. The cases are expected to achieve an AGR of more than 1% during the period 2022-2032. VTE, comprised of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a potentially fatal condition that impedes blood flow by causing blood clots (thrombosis). VTE can occur in men and women of all ages, with children at very low risk, and adults aged 40...
-
Sector Analysis
Atrial Fibrillation Epidemiology Analysis and Forecast to 2032
Atrial Fibrillation Market Report Overview In the 8MM, there were 14,457,906 total prevalent cases of Atrial Fibrillation in 2022. The cases are expected to achieve an AGR of more than 2% during the period 2022-2032. Atrial fibrillation (AF) is characterized by an irregular and often very rapid heart rhythm, or arrhythmia, that can lead to blood clots in the heart. This increases the risk of stroke, heart failure, and other cardiac complications. In AF patients, the normal beating in the...
-
Sector Analysis
Venous Thromboembolism Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2032
Venous Thromboembolism Market Report Overview Venous Thromboembolism market size across the 7MM was valued at $3.57 billion in 2022 and is expected to achieve a CAGR of more than 2% during 2022-2032. The US is the most significant contributor to that revenue due to the large size of the VTE patient population in the US as well as the higher overall price of drugs as compared to the 5EU and Japan. Venous Thromboembolism Market Outlook, 2022-2032 ($ Billion) To gain...
-
Sector Analysis
Myocardial Infarction (MI) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Myocardial Infarction Marketed Drugs Overview Myocardial infarction (MI), colloquially known as "heart attack," is caused by decreased or complete cessation of blood flow to a portion of the myocardium. In most cases, this occurs as a result of occlusive coronary atherosclerosis superimposed with a luminal thrombus. MI may be "silent," and go undetected, or it could be a catastrophic event leading to hemodynamic deterioration and sudden death. Most MIs are due to underlying coronary artery disease, the leading cause of...
-
Product Insights
Aneurysm Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Aneurysm Clinical Trials Market Report Overview The aneurysm clinical trial market research report provides an overview of the aneurysm clinical trials scenario. The report provides top-line data relating to the clinical trials on the aneurysm. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
-
Sector Analysis
Heart Failure (HF) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Heart Failure (HF) Marketed and Pipeline Drugs Market Report Overview Heart Failure (HF) is a critical clinical condition where certain structural and functional abnormalities in the heart impair its ability to meet systemic circulation. The various causes that contribute to these abnormalities are hypertension, arrythmia, valvular heart disease, and risk factors including high cholesterol, infection, and genetic factors. The Heart Failure (HF) marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with...
-
Product Insights
Peripheral Artery Occlusive Disease (PAOD) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
PAOD Clinical Trials Market Report Overview The PAOD clinical trial market research report provides an overview of the PAOD clinical trials scenario. The report provides top-line data relating to the clinical trials on PAOD. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
-
Product Insights
Pulmonary Arterial Hypertension Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
Pulmonary Arterial Hypertension Clinical Trials Market Report Overview The pulmonary arterial hypertension clinical trial market research report provides an overview of the pulmonary arterial hypertension clinical trials scenario. The report provides top-line data relating to the clinical trials on pulmonary arterial hypertension. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points...
-
Sector Analysis
Pulmonary Arterial Hypertension Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029
Pulmonary Arterial Hypertension Market Overview The Pulmonary Arterial Hypertension (PAH) market size across the 7MM was valued at $4.6 billion in 2019 and is forecast to grow at a CAGR of more than 4% during 2019-2029. Pulmonary Arterial Hypertension Market Outlook To gain more information on the Pulmonary Arterial Hypertension market forecast, download a free report sample The Pulmonary Arterial Hypertension market research report provides an overview of PAH, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management. Market Size (2019)...
-
Product Insights
Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. The Hypertension pipeline market research report provides comprehensive information on the therapeutics under development for Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases....
-
Product Insights
Myocardial Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Myocardial fibrosis is an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts. The Myocardial Fibrosis pipeline market research report provides comprehensive information on the therapeutics under development for Myocardial Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally,...
-
Product Insights
Acute Ischemic Stroke Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
The Acute Ischemic Stroke clinical trial market research report provides an overview of the Acute Ischemic Stroke clinical trials scenario. The report provides top-line data relating to the clinical trials on Acute Ischemic Stroke. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
-
Product Insights
Pulmonary Embolism Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
The pulmonary embolism clinical trial market research report provides an overview of the pulmonary embolism clinical trials scenario. The report provides top-line data relating to the clinical trials on pulmonary embolism. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
-
Product Insights
Hypertrophic Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hypertrophic Cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickened heart muscles make it harder for the heart to pump blood. Symptoms include chest pain, especially during exercise, the sensation of rapid, fluttering, or pounding heartbeats, and heart murmur. HCM usually is inherited. Treatment includes beta blockers, calcium channel blockers and blood thinners. The HCM pipeline drugs market research report provides comprehensive information on the therapeutics under development for Hypertrophic Cardiomyopathy, complete...
-
Product Insights
Atherosclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Atherosclerosis (or arteriosclerotic vascular disease) may occur with symptoms including chest pain (angina), pain in the leg, arm, and anywhere else that an artery is blocked, shortness of breath, fatigue, confusion (if the blockage affects circulation to the brain) and muscle weakness in the legs from lack of circulation. The Atherosclerosis pipeline drugs market research report outlays comprehensive information on the Atherosclerosis targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA)...
-
Product Insights
Stroke Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Stroke can occur with symptoms including sudden numbness in their face or limbs, particularly down one side of their body. The sufferer may appear confused and have trouble talking or understanding what is being said to them. They may have vision problems, and trouble walking or keeping their balance. The Stroke pipeline drugs market research report outlays comprehensive information on the Stroke targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA)...
-
Product Insights
Critical Limb Ischemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality...
-
Product Insights
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Peripheral vascular disease (PVD) refers to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh, or calf muscles after activity, such as walking or climbing stairs (intermittent claudication), leg numbness or weakness, coldness in the lower leg or foot, especially when compared with the other side, sores on toes, feet or legs that won't heal, slower growth of toenails and erectile dysfunction in men. The PVD pipeline drugs...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.